Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: Results from a 14-week, randomized, double-blind, placebo-controlled study
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
This 14-week, phase 3, double-blind, randomized, controlled trial evaluated sodium oxybate (SXB) 4.5 and 6g per night versus placebo in patients with fibromyalgia (FM). SXB is the sodium salt of γ-hydroxybutyrate (GHB). GHB is an endogenous compound, synthesized from γ-aminobutyric acid (GABA) and found broadly in the central nervous system and body. Among 548 randomized patients, a ≥30% reduction in pain was experienced by 54.2% and 58.5% of patients treated with SXB 4.5 and 6g, respectively, versus 35.2% for placebo with a 100-mm Visual Analog Scale (VAS) (P<0.001 for both comparisons). Relative to placebo, both SXB doses significantly reduced fatigue (with a 100-mm VAS; P<0.001) and sleep disturbance (with the Jenkins Sleep Scale; P<0.001), and resulted in significant improvements in function as measured by the FM Impact Questionnaire (P=0.003 and P=0.001 for 4.5 and 6 g per night, respectively). On the Short-Form 36 Health Survey, SXB-related improvement was significant on the Physical, but not the Mental, Component Scale. The proportion of patients who reported a global improvement of "much" or "very much" better on the Patient Global Impression of Change was significantly greater in both SXB groups versus placebo (P<0.001). Headache, nausea, dizziness, vomiting, diarrhea, anxiety, and sinusitis were the most commonly reported adverse events, with an incidence at least twice that of placebo. These results expand the evidence from previous clinical trials suggesting that SXB is effective and safe in FM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471 · cited 2×
“IMMPACT considers a 30% pain reduction, experienced by more than half of SXB-treated patients, to be a moderate clinically important change and a 50% pain reduction, experienced by more than 40% of SXB-treated patients, to be of substantial clinical importance [15].”
BackgroundMethodUsing the Berlin Questionnaire To Identify Patients at Risk for the Sleep Apnea Syndrome
Netzer, N. C., Stoohs, R. A., Netzer, C. M., Clark, K., & Strohl, K. P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00002 · Cited by 2,973 · cited 1×
“During screening at the investigative sites, evaluation for eligibility included assessment for sleep apnea by clinical judgment, in conjunction with the Berlin Questionnaire [35].”
MethodThe RAND-36 measure of health-related quality of life
Hays, R. D., & Morales, L. S. (2001) · Annals of Medicine · doi:10.3109/07853890109002089 · Cited by 1,460 · cited 1×
“5–5 points has been proposed for SF-36 subscales [19].”
BackgroundAn Instrument to Measure Functional Status Outcomes for Disorders of Excessive Sleepiness
(1997) · Sleep · doi:10.1093/sleep/20.10.835 · Cited by 881
An internet survey of 2,596 people with fibromyalgia
Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J., & Matallana, L. (2007) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-8-27 · Cited by 865 · cited 2×
“FM is often associated with comorbidities including irritable bowel syndrome, irritable bladder, restless legs syndrome, anxiety, and depression [6,60].”
BackgroundResultFibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes
Yunus, M. B. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.12.009 · Cited by 780
Prevalence of Fibromyalgia: A Survey in Five European Countries
Branco, J. C., Bannwarth, B., Failde, I., Abello Carbonell, J., Blotman, F., Spaeth, M., Saraiva, F., Nacci, F., Thomas, E., Caubère, J.-P., et al. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.12.003 · Cited by 685
Elevated cerebrospinal fluid levels of substance p in patients with the fibromyalgia syndrome
Russell, I. J., Orr, M. D., Littman, B., Vipraio, G. A., Alboukrek, D., Michalek, J. E., Lopez, Y., & Mackillip, F. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371106 · Cited by 679 · cited 1×
“Neurochemical cerebrospinal fluid aberrations were documented in patients with FM, including deficient dopamine, serotonin, and norepinephrine metabolites [43], as well as elevated levels of the nociceptive neurotransmitter substance P [41] and nerve growth factor [17].”
Background
Cited by
Fibromyalgia: A Clinical Review
Clauw, D. J. (2014) · JAMA · doi:10.1001/jama.2014.3266 · Cited by 1,674
AAPT Diagnostic Criteria for Fibromyalgia
Arnold, L. M., Bennett, R. M., Crofford, L. J., Dean, L. E., Clauw, D. J., Goldenberg, D. L., Fitzcharles, M.-A., Paiva, E. S., Staud, R., Sarzi-Puttini, P., et al. (2019) · The Journal of Pain · doi:10.1016/j.jpain.2018.10.008 · Cited by 420
The neurobiology of central sensitization
Harte, S. E., Harris, R. E., & Clauw, D. J. (2018) · Journal of Applied Biobehavioral Research · doi:10.1111/jabr.12137 · Cited by 394
Fibromyalgia Pathogenesis and Treatment Options Update
Chinn, S., Caldwell, W., & Gritsenko, K. (2016) · Current Pain and Headache Reports · doi:10.1007/s11916-016-0556-x · Cited by 296
Fibromyalgia and related conditions
Clauw, D. J. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.03.014 · Cited by 259
Metadata
- Authors
- Russell, J. I., Holman, A. J., Swick, T. J., Alvarez-Horine, S., Wang, G. Y., & Guinta, D.
- Venue
- Pain
- Published
- 2011-05
- Volume
- 152
- Issue
- 5
- Pages
- 1007-1017
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2012390284
- Cited by
- 103
- References
- 17
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: Results from a 14-week, randomized, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1016/j.pain.2010.12.022
- The paper
- Russell, J. I., Holman, A. J., Swick, T. J., Alvarez-Horine, S., Wang, G. Y., & Guinta, D. (2011). Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: Results from a 14-week, randomized, double-blind, placebo-controlled study. Pain. https://doi.org/10.1016/j.pain.2010.12.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.